You Lu

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana et al. · The Lancet Respiratory Medicine · 2019 · 272 citations

Medicine, Oncology, Pharmacology +12

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang et al. · Journal of Thoracic Oncology · 2020 · 156 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +12

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer

Hui Wang, Zhuoran Yao, Kai Kang et al. · Med · 2024 · 42 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail

Xue Meng, Jianhua Wang, Xindong Sun et al. · Radiotherapy and Oncology · 2013 · 27 citations · Full text

Medicine, Oncology, Pharmacology +14

Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score

Yongmei Liu, Lei Deng, Xiaojuan Zhou et al. · Oncotarget · 2017 · 24 citations · Full text

Medicine, Oncology, Radiation Oncology +12